Article
DOJ Directive Signals FDA-Regulated Industries May Be Subject To Enhanced Scrutiny
The U.S. Department of Justice's National Fraud Enforcement Division has issued a new directive that explicitly references the Federal Food, Drug, and Cosmetic Act, signaling potential increased scrutiny of FDA-regulated companies. This development, combined with a recent memorandum of understanding between the FDA and SEC, suggests a coordinated federal enforcement approach that could significantly impact drug and device manufacturers across the healthcare supply chain.
Holland & Knight